Supports medical research at OSUCCC-The James on treatment of blood cancers, specifically chronic lymphocytic leukemia (CLL), as undertaken by Dr. John Byrd (or successor). Initiatives supported include (but not limited to): lab support, novel therapeutics, molecular pathogenesis, drug resistance, cell therapies, etc., leading to rapid initial preclinical testing of new therapies.